Although clinical trials (Table 1) and more recent meta-analyses (Bergmark et al., 2019; Han et al., 2019) provide evidence for a cardioprotective effect of metformin on the cardiovascular outcome in T2D patients, the available data are less comprehensive compared to DPP4i, GLP1-RA, and SGLT2i (Harrington et al., 2018). Here, GLP1R is linked to type 2 diabetes mellitus.